Matching placebo control

Phase 2

Matching placebo control is one of 3 therapeutic programs targeting Uncontrolled Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Uncontrolled HypertensionRecruiting

Uncontrolled HypertensionPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Uncontrolled Hypertension

#DrugCompanyPhaseTrials

Baxfendy

AstraZeneca

Approved

1 2

RTN-001

RRetension Pharmaceuticals. Inc.

Phase 2

1 3

Matching placebo control

RRetension Pharmaceuticals. Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Uncontrolled Hypertension

NCT07142356

Clinical

Trials by Indication[1]

Uncontrolled Hypertension1 trial

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

Recruiting·RRetension Pharmaceuticals. Inc.·Phase 2·NCT07142356·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Matching placebo control. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Matching placebo control. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Retension Pharmaceuticals. Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RRetension Pharmaceuticals. Inc.

Matching placebo control

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Uncontrolled Hypertension1 trial

References

Drug Info

Quick Facts

Related News